XTX Topco Ltd Has $334,000 Position in Certara, Inc. (NASDAQ:CERT)

XTX Topco Ltd increased its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 202.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,342 shares of the company's stock after buying an additional 20,970 shares during the quarter. XTX Topco Ltd's holdings in Certara were worth $334,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Mariner LLC increased its holdings in Certara by 26.5% in the fourth quarter. Mariner LLC now owns 23,823 shares of the company's stock valued at $254,000 after buying an additional 4,991 shares in the last quarter. Townsquare Capital LLC increased its stake in Certara by 7.7% during the fourth quarter. Townsquare Capital LLC now owns 49,219 shares of the company's stock worth $524,000 after acquiring an additional 3,526 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of Certara by 57.2% during the 4th quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock worth $77,000 after purchasing an additional 2,624 shares during the period. Raymond James Financial Inc. purchased a new stake in Certara during the 4th quarter worth $3,628,000. Finally, Bank of Montreal Can grew its stake in shares of Certara by 9.1% in the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock valued at $212,000 after buying an additional 1,670 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Performance

CERT traded up $0.04 during trading on Tuesday, hitting $13.77. The stock had a trading volume of 304,001 shares, compared to its average volume of 1,219,436. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $17.94. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market cap of $2.22 billion, a PE ratio of -68.78, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a 50 day simple moving average of $11.65 and a 200-day simple moving average of $11.59.

Analysts Set New Price Targets

Several research analysts recently commented on CERT shares. KeyCorp boosted their price target on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Robert W. Baird increased their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Barclays decreased their price target on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.17.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.